Peripheral vascular outcomes in the PLATO trial: Update from the FDA ticagrelor complete response review

American Journal of Therapeutics

Volumn 19, Issue 2, 2012, Pages 160-161

  Serebruany, Victor L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; CLAUDICATION; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; INTESTINE ISCHEMIA; KIDNEY ISCHEMIA; LOADING DRUG DOSE; LUNG EMBOLISM; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA ISCHEMIA; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MULTICENTER STUDIES AS TOPIC; PERIPHERAL ARTERIAL DISEASE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84858780019     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318245ce6c     Document Type: Review

References (5)

1. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
2. Aronow WS. Antiplatelet therapy in the treatment of atherothrombotic disease: considering the evidence. Geriatrics. 2007;62:12-24.
3. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996;348:1329-1339.
4. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-1015.
5. The FDA ticagrelor review of complete response. Available for download at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022433Orig1s000TOC. cfm. Accessed December 8, 2011.